<DOC>
	<DOCNO>NCT02184312</DOCNO>
	<brief_summary>Study determine pharmacokinetic property 200 mg ( 2 x 100 mg tablet daily ) 300 mg ( 3 x 100 mg tablet daily ) Nevirapine extend release formulation estimate relative bioavailability formulation compare 200 mg VIRAMUNE® tablet well 400 mg Nevirapine extend release tablet</brief_summary>
	<brief_title>Pharmacokinetic Properties Two Dosages Nevirapine Extended Release ( XR ) Formulations Compared VIRAMUNE® Tablet Well Nevirapine XR Tablet Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory ; value within normal range deviate normal without clinical relevance consider investigator Values Liver Function Test ( LFT ) within normal range Age ≥18 Age ≤60 year Body Mass Index ( BMI ) ≥18.5 BMI ≤29.9 kg/m2 Subjects must agree minimize risk female partner become pregnant first dose day 3 month completion post study medical examination . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive since least two month ) Signed date write informed consent prior admission study accordance Good clinical practice ( GCP ) local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder clinical relevance Surgery gastrointestinal tract ( except appendectomy herniotomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Participation trial BI 1100.1485 intake Nevirapine Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor Torsades de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) History disease affect present situation Inability understand protocol requirement , instruction studyrelated restriction , nature , scope , possible consequence study Unlikely comply protocol requirement , instruction studyrelated restriction ; e.g. , uncooperative attitude , inability return followup visit , improbability complete study Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct study Vulnerable subject ( e.g . person keep detention )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>